Taro Igarashi

6PUBLICATIONS
11CO-AUTHORS
NaturopathyCancer therapy (excl. chemotherapy and radiation therapy)PharmacogenomicsMedical molecular engineering of nucleic acids and proteinsNeurology and neuromuscular diseases
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (6)

|Mar 24, 2026
Real-world persistence of vibegron in patients aged ≥ 80 years with overactive bladder: a multicenter cohort study.

Taro Igarashi, Yuto Nukariya, Shota Kawano

|Apr 09, 2025
Evaluating CRPC Definition: Comparing Upfront ARSI and Conventional Hormonal Therapy for Metastatic Hormone Sensitive Prostate Cancer (mHSPC) in Real World Propensity Score Matched Cohort.

Tatsuya Shimomura, Fumihiko Urabe, Katsuki Muramoto

|Apr 06, 2025
PSA Absolute Value Versus PSA Response Rate: Which Is More Valuable for Estimating Survival Outcomes With ARPI Treatment for Metastatic Hormone-Sensitive Prostate Cancer (mHSPC) in Real-World Analyses?

Tatsuya Shimomura, Naoki Otsuka, Fumihiko Urabe

|Jul 15, 2024
Benign prostatic hyperplasia nodules in patients treated with celecoxib and/or finasteride have reduced levels of NADH dehydrogenase [ubiquinone] iron-sulfur protein 3, a mitochondrial protein essential for efficient function of the electron transport chain.

Teresa T Liu, Taro Igarashi, Nathalie El-Khoury

|May 28, 2024
Effects of oral administration of nonselective Trk inhibitor on bladder overactivity in rodent models of prostatic inflammation.

Taro Igarashi, Shinsuke Mizoguchi, Kanako Matsuoka

|Oct 01, 2021
Therapeutic effects of nerve growth factor-targeting therapy on bladder overactivity in rats with prostatic inflammation.

Taro Igarashi, Pradeep Tyagi, Shinsuke Mizoguchi

Pageof 1

Frequent Collaborators

2 joint publications

Naoki Yoshimura

2 joint publications

Tatsuya Shimomura

2 joint publications

Fumihiko Urabe

2 joint publications

Takafumi Yanagisawa